Catheter Precision posts Q3 net loss $4.1M, revenue $96K; warrants raise $4.9M

Catheter Precision, Inc.

Sales revenue for Q3 2024 was ~$96K, net loss $4.1M (including $1.7M non-cash charges); nine-month net loss $11.0M.
Cash at Sept 30 was $1.3M; on Oct 25, 2024, warrant exercise raised gross proceeds of $4.9M.
Company has 87 hospitals in pipeline; 32 institutions in ongoing evaluations; CE Mark for LockeT expected by end of Q1 2025.
Commercial team includes new CCO Marie-Claude Jaques; VIVO procedures ongoing in multiple European countries.
Over 130 patients enrolled in LockeT II comparative study; initial LockeT study published in JCE in August.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.